Abstract The coronavirus 2019 (COVID-19) pandemic is expected to linger. Decisions
regarding initiation or continuation of disease-modifying therapy for multiple sclerosis have …

Multiple sclerosis (MS) is more common in women than men and is most commonly
diagnosed in early adulthood; thus, many patients will not have completed their families at …

Background Treatment with natalizumab once every 4 weeks is approved for patients with
relapsing-remitting multiple sclerosis, but is associated with a risk of progressive multifocal …

Objective To use the large dataset from the Tysabri Outreach: Unified Commitment to Health
(TOUCH) program to compare progressive multifocal leukoencephalopathy (PML) risk with …

Objective To evaluate the clinical consequences of extended interval dosing (EID) of
ocrelizumab in relapsing-remitting multiple sclerosis (RRMS) during the coronavirus disease …

Progressive multifocal leukoencephalopathy (PML) is a rare, devastating demyelinating
disease of the CNS caused by the JC virus (JCV) that occurs in patients with compromised …

Multiple sclerosis is a chronic demyelinating disease of the central nervous system (CNS)
with an autoimmune component. Among the recent disease-modifying treatments available …

The Canadian Multiple Sclerosis Working Group has updated its treatment optimization
recommendations (TORs) on the optimal use of disease-modifying therapies for patients …

Objective Ocrelizumab inhibits relapsing multiple sclerosis when administered every six
months. Based on potential similar memory B cell depletion mechanisms with cladribine and …

With evolving diagnostic criteria and the advent of new oral and parenteral therapies for MS,
most current diagnostic and treatment algorithms need revision and updating. The diagnosis …